Early onset of antipsychotic response in the treatment of acutely agitated patients with psychotic disorders.

While the efficacy of antipsychotic medications for the treatment of psychosis is generally established, the speed of onset of antipsychotic action remains controversial. The objective of this study was to evaluate the early response (within the first 24 h) in psychosis with ziprasidone IM treatment, and to determine whether this early effect is distinct from a reduction in agitation symptoms.
In a 24-h, double-blind study, hospitalized patients with psychotic disorder and acute agitation were randomized to treatment with fixed doses of IM ziprasidone: 2 mg (N=38) or 20 mg (N=41). Efficacy assessments were based on the PANSS positive subscale and PANSS early psychosis factor score (conceptual disorganization, hallucinatory behavior, and unusual thought content) at 4 and 24 h.
Ziprasidone IM demonstrated a significant dose-related effect (20 mg vs. 2 mg) on both the PANSS early psychosis factor score and the PANSS positive subscale at the first post-baseline time point (4 h), and at 24 h (all p<0.05). There was a significant direct effect of ziprasidone IM on early psychosis at 24 h (p<0.05), distinct from improvement in agitation symptoms.
These findings suggest, in addition to an early reduction in acute agitation, ziprasidone IM may be associated with a more rapid improvement in psychotic symptoms than previously reported, thus lending further support to the emergent hypothesis of early psychosis improvement in antipsychotic treatment.
AuthorsOfer Agid, Shitij Kapur, Lewis Warrington, Antony Loebel, Cynthia Siu
JournalSchizophrenia research (Schizophr Res) Vol. 102 Issue 1-3 Pg. 241-8 (Jul 2008) ISSN: 0920-9964 [Print] Netherlands
PMID18495436 (Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References
  • Antipsychotic Agents
  • Piperazines
  • Thiazoles
  • ziprasidone
  • Acute Disease
  • Adult
  • Antipsychotic Agents (therapeutic use)
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Hospitalization
  • Humans
  • Male
  • Piperazines (therapeutic use)
  • Psychiatric Status Rating Scales (statistics & numerical data)
  • Psychomotor Agitation (diagnosis, drug therapy, psychology)
  • Psychotic Disorders (diagnosis, drug therapy, psychology)
  • Thiazoles (therapeutic use)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: